We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Cystic Fibrosis, Pancreatic Treatment Guidance
FDA Issues Cystic Fibrosis, Pancreatic Treatment Guidance
April 21, 2006
The FDA issued final guidance April 14 laying out the requirements companies must meet when submitting new drug applications (NDAs) for drugs to treat cystic fibrosis, chronic pancreatitis and pancreatic tumors, as well as those for patients who have undergone a pancreatectomy.